Results 201 to 210 of about 704,484 (268)

A Spatially Directed Microneedle Patch Enables Intratumoral Co‐Delivery of FOLFIRINOX, Surufatinib, and Anti‐PD‐1 for Chemo‐Immunotherapy of Pancreatic Ductal Adenocarcinoma

Advanced Science, EarlyView.
A double‐layered shell‐core microneedle patch is developed to co‐deliver FOLFIRINOX, surufatinib, and anti‐PD‐1 for localized chemo‐immunotherapy of PDAC. This strategy achieves sustained tumor suppression, reduces metastasis, and reprograms the TME by enhancing CD8+ T‐cell infiltration and inhibiting Tregs and M2 macrophages infiltration, while ...
Tingting Kong, Ximo Xu, Xiao Zhang, Chuntao Wu, Zhengjun Qiu, Beiyuan Hu, Zihao Qi, Qiang Tian, Yuqin Yang, Hanguang Dong, Fei Wu, Tuo Jin, Yan Zheng, Jiang Long   +13 more
wiley   +1 more source

Long-Term Safety of Anti-Interleukin-1 Medications in Children with Rheumatic Diseases: a Systematic Review. [PDF]

Paediatr Drugs
Isa M, Tiller GM, Liew DFL, Renton WD.
europepmc   +1 more source

Comparative effects of adipose-derived mesenchymal stem cells and their exosomes on interleukin-1 beta-induced testicular inflammation in rats: An experimental study. [PDF]

Int J Reprod Biomed
Bilabari M, Mohammadnejad D, Rahbarghazi R, Shafaei H.   +3 more
europepmc   +1 more source

Interleukin-1 receptor type 1 inhibition improves blood pressure, fetal growth and immune balance in placental ischemic rats. [PDF]

Am J Physiol Regul Integr Comp Physiol
Robbins M, Deer E, Thompson DG, McKay JG, Williams JM, Cornelius DC.   +5 more
europepmc   +1 more source

The Golden Card of Interleukin-1 Blockers in Systemic Inflammasomopathies of Childhood. [PDF]

Int J Mol Sci
Rigante D.
europepmc   +1 more source

Phenotypic Changes in a Monocyte Cluster with High Interleukin-1 Beta Expression during Long-Term Anti-CD20 Therapy. [PDF]

Ann Neurol
Waede M, Kingo C, Damsbo K, Joergensen MU, Oubounyt M, Gjerstorff M, Thomassen M, Baumbach J, Moeller JB, Elkjaer ML, Illes Z.   +10 more
europepmc   +1 more source

Inflammatory mechanisms contribute to long-term cognitive deficits induced by perinatal asphyxia via interleukin-1. [PDF]

Neuropsychopharmacology
Kelemen H, Balla GY, Demeter K, Sipos E, Buzás-Kaizler A, Biró L, Aliczki M, Orsolits B, Kerényi Á, Balogh Z, Pászthy-Szabó B, Pejtsik D, Hegyi L, Szigeti K, Máthé D, Padmanabhan P, Bödör C, Fekete A, Szabó M, Kaila K, Dénes Á, Mikics É.   +21 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Interleukin-1

The International Journal of Biochemistry & Cell Biology, 1998
Interleukin 1 (IL1) is a primary regulator of inflammatory and immune responses. Via its type I receptor it activates specific protein kinases, including the NF kappa B inducing kinase (NIK) and three distinct mitogen-activated protein (MAP) kinase cascades.
E, Stylianou, J, Saklatvala
openaire   +3 more sources

Interleukin 1: the first interleukin

Immunology Today, 1990
The name 'interleukin' and the designation of interleukin 1 (IL-1) derived from the Second International Lymphokine Workshop held in Switzerland in 1979. Since then interest in the original interleukin (IL-1) has increased exponentially as measured by the numbers of publications and meetings.
F S, di Giovine, G W, Duff
openaire   +2 more sources

Interleukin 1 is more than an interleukin

Immunology Today, 1982
Gery and co-workers(1) first described lymphocyte activating factor (LAF) in 1972, as an activity produced by cultured human peripheral blood adherent leukocytes which was directly mitogenic for murine thymocytes but not for immunocompetent peripheral lymphocytes.
J J, Oppenheim, I, Gery
openaire   +2 more sources